Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (27427)	1/16/1999 8:09:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

The LLY deal is very broad and there are many research programs. There are 30-40 LGND scientists and an equal number of LLY scientists working on the various programs. I believe that the royalties are tied to starting a diabetes program with Targretin or filing IND's for LGD1268 and/or LGD1324. I suspect that more was done with the European diabetes study to determine which compound will start the diabetes trial and more pre-clinical work was done to determine which second generation compound (LGD1268 or LGD1324), will enter the clinic first. LGND did move forward with Targretin in breast cancer, but since LGND is developing that indication on its own, there was no associated royalty.